ArticleEuropean journal of neurology2025
Prognostic Implications of Myositis-Specific Autoantibodies on Mortality, Relapse, and Remission in Dermatomyositis Patients.
Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Magnetic resonance imaging changes of thigh muscles in dermatomyositis patients with anti-Mi2 antibody.Annals of medicine · 2026Article
- Flares and definition of worsening in inflammatory myopathies: a narrative review of the literature.Rheumatology (Oxford, England) · 2026Review
- Prognostic Implications of Myositis-Specific Autoantibodies on Mortality, Relapse, and Remission in Dermatomyositis Patients.European journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectivesTo explore the clinicopathological features and treatment prognosis including death, relapse and remission of dermatomyositis (DM) based on myositis-specific autoantibody (MSAs) stratification.
methodsPatients with DM come from a provincial neuromuscular center in northern China. Patients who underwent biopsy from 2010 to 2023 were collected, and the follow-up time was all more than 6 months. Clinical characteristics, serum samples, and muscle biopsies were collected. Kaplan-Meier analysis, Cox regression, and competing risk model were used for analysis.
resultsOur study included 140 patients with DM. Among the 25 juvenile patients, 9 (36%) were anti-NXP2 antibody positive. About 80.95% of the patients with anti-TIF1-γ antibodies had neck flexion weakness. Patients with anti-Mi-2 antibodies showed a predominance of severe muscle fiber necrosis/regeneration (76.19%) rather than perifascicular atrophy (14.29%). Compared to the seronegative subgroup, the short- and long-term risks of death were higher in anti-TIF1-γ-positive patients, and the 3-year risk of death was higher in anti-MDA5 patients. The short- and long-term dangers of relapse were consistently higher in anti-Mi-2-positive patients, with a higher 3-year relapse risk in the anti-NXP2 subgroup. In the case of death as a competing risk of relapse, patients with anti-Mi-2 and patients with anti-NXP2 had higher short- and long-term risks of relapse. No difference was found in the clinical remission rate based on the DM-MSA stratification.
conclusionEvaluating the characteristics and prognosis of DM subgroups based on serum MSA stratification is helpful for patient management and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.